Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monoclonal antibodies.

M D Scharff, S Roberts, P Thammana

    The Journal of Infectious Diseases
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    A novel technology enables the indefinite, large-scale production of homogeneous antibodies. This advancement enhances the reliability and sensitivity of immunoassays for infectious disease diagnostics and research.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Generation and maintenance of hybridomas.

    Immunology today·2014
    Same author

    The production of more useful monoclonal antibodies I. Modifications of the basic technology.

    Immunology today·2014
    Same author

    The production of more useful monoclonal antibodies 2. The use of somatic-cell genetic and recombinant-DNA technology to tailor-make monoclonal antibodies.

    Immunology today·2014
    Same author

    The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair.

    Oncogene·2013
    Same author

    An efficient homologous recombination vector pTV(I) contains a hot spot for increased recombinant protein expression in Chinese hamster ovary cells.

    Gene·2001
    Same author

    Testing the reverse transcriptase model of somatic mutation.

    Molecular immunology·2001
    Same journal

    NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

    The Journal of infectious diseases·2026
    Same journal

    Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

    The Journal of infectious diseases·2026
    Same journal

    Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

    The Journal of infectious diseases·2026
    Same journal

    Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

    The Journal of infectious diseases·2026
    Same journal

    Type 3 fimbrial regulation underpins anti-MrkA immunotherapeutic efficacy in experimental Klebsiella pneumoniae infection.

    The Journal of infectious diseases·2026
    Same journal

    Rationalising heterogeneity in Staphylococcus aureus bacteraemia: current progress and future goals.

    The Journal of infectious diseases·2026
    See all related articles

    Area of Science:

    • Immunology
    • Biotechnology
    • Infectious Disease Diagnostics

    Background:

    • Serologic reagents are crucial for diagnosing, treating, and understanding infectious disease patterns.
    • Current antibody production methods can be limited in scale and availability.

    Purpose of the Study:

    • To introduce a new technology for generating homogeneous antibodies.
    • To highlight the potential of this technology to improve immunoassays and in vivo applications.

    Main Methods:

    • Development of a novel antibody generation technique.
    • Focus on achieving homogeneous antibody production in large, indefinite quantities.

    Main Results:

    • Successful generation of homogeneous antibodies using the new technology.

    Related Experiment Videos

  • Demonstrated potential for large-scale and indefinite antibody availability.

    • Conclusions:

    • The developed technology offers a reliable and sensitive source of antibodies for immunoassays.
    • This advancement may lead to safer in vivo applications and improved infectious disease management.